CagriSema Dr EXPLAINS How This GLP 1 + Amylin Drug Differs From Wegovy
A short explainer from a lifestyle medicine channel on how CagriSema pairs semaglutide with an amylin-pathway drug, with trial figures, side effects and its investigational status.
With Dr. G
Key moments
Tap a moment to play the video from there.
- 0:00What CagriSema combinesThe host introduces CagriSema as a weekly injection pairing semaglutide with cagrilintide and asks how it differs from Wegovy and Zepbound.
- 0:21Two satiety pathways explainedHe describes semaglutide as a GLP-1 agonist and cagrilintide as an amylin analog acting on calcitonin receptors, calling the pairing a multipathway strategy.
- 1:34REDEFINE 1 and 2 resultsHe cites up to about 22.7% average weight loss over 68 weeks without diabetes, and around 15.7% in certain analyses in people with type 2 diabetes.
- 3:14Comparison with semaglutide aloneHe says CagriSema is designed to outperform semaglutide alone and cites early 2026 REIMAGINE 2 reporting of larger A1C and weight reductions.
- 4:04What patients may noticeHe says deeper satiety could mean smaller portions and fewer cravings, but that tolerability may limit use for some people.
- 4:42Side effects and nutritionHe lists gastrointestinal effects, dehydration and low energy, and stresses protein, resistance training and monitoring to protect lean mass.
- 5:49Investigational status and fitHe says the drug is still in large clinical programs and suggests it may suit people needing more than GLP-1 alone or those with type 2 diabetes.
- 6:55Takeaways and clinic contactHe sums up CagriSema as a combination of two pathways rather than a new category, then promotes his South Florida practice.
What the video says
The host describes CagriSema as an investigational weekly injection that combines two drugs in one fixed dose: semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin analog that also acts on calcitonin receptors. He frames the point of the combination as adding a second fullness pathway to GLP-1 signaling, and says it is not simply a stronger GLP-1.
On evidence, he cites public reporting from the phase 3 REDEFINE 1 trial in adults with obesity or overweight and no type 2 diabetes. It ran 68 weeks, and its highest efficacy analysis showed average weight loss of up to about 22.7% on the full dose. For REDEFINE 2, in people with type 2 diabetes, he cites around 15.7% in certain analyses. He says people with diabetes often lose less weight on any therapy, and that trial averages hide the effects of dose escalation, adherence and dropout. He also mentions early 2026 reporting from REIMAGINE 2, which he says found larger reductions in hemoglobin A1C and body weight than semaglutide alone.
The host expects the main side effects to be gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux and reduced appetite. These are most likely during dose escalation, and stronger appetite suppression could make tolerability the limiting factor for some people. He also warns about dehydration, low energy, loss of lean mass and nutritional gaps, and says large weight loss calls for protein targets, resistance training, hydration and close monitoring, especially in older adults.
He is clear that CagriSema is still investigational and that durability and real-world tolerability are not yet known. He suggests it may suit people who need more than semaglutide alone, or people with type 2 diabetes where weight and glucose both matter, with the decision left to the individual and their doctor. The video ends with a promotion for his South Florida clinic.
On each compound
CagriSema0:00
The host presents it as an investigational fixed-dose weekly injection combining semaglutide and cagrilintide. He cites up to about 22.7% average weight loss in REDEFINE 1 and reports of larger A1C and weight reductions than semaglutide in REIMAGINE 2.
See how your DNA reads CagriSemaSemaglutide0:21
The host describes it as a GLP-1 receptor agonist that he says helps people feel full sooner and reduces cravings. He also says it improves glucose regulation and insulin sensitivity, and he treats it as the comparator for CagriSema.
See how your DNA reads SemaglutideCagrilintide0:21
The host calls it a long-acting amylin analog that also activates calcitonin receptors. He says it adds a second satiety pathway to GLP-1 signaling.
See how your DNA reads Cagrilintide“this is not a stronger GLP-1. It's a multipathway satiety strategy.”
“the goal is not eat as little as possible.”
What this video doesn’t settle
- The host gives no numbers for the REIMAGINE 2 comparison with semaglutide, so the size of any added benefit is not established here.
- All trial figures are quoted from public reporting without showing the data, and he does not say whether they came from the full study population or a subset.
- No rates are given for any side effect or for people stopping the drug, so how often the problems occur is unclear.
Questions this video answers
How is CagriSema different from Wegovy?
According to the host, Wegovy is semaglutide alone, while CagriSema is semaglutide plus cagrilintide, an amylin analog. He says the aim is a second satiety pathway rather than a stronger GLP-1.
How much weight did people lose on CagriSema in the REDEFINE trials?
The host cites public reporting of average weight loss of up to about 22.7% over 68 weeks in REDEFINE 1, in adults without type 2 diabetes. For REDEFINE 2, in people with type 2 diabetes, he cites around 15.7% in certain analyses.
What side effects of CagriSema does the video mention?
The host expects mostly gastrointestinal effects: nausea, vomiting, diarrhea, constipation, reflux and decreased appetite. He adds that dehydration and low energy can occur, and that effects tend to peak during dose escalation.
Is CagriSema approved or available yet?
The host describes it as investigational and still working through large clinical programs. He raises the question of when it will be available but does not give a date.
Does CagriSema help more than semaglutide in type 2 diabetes?
The host says early 2026 topline reporting from REIMAGINE 2 described larger reductions in hemoglobin A1C and body weight than semaglutide alone. He gives no figures for that comparison.
Video by Dr. G's Lifestyle Medicine Network on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
